RAD51B and breast carcinoma: Our findings demonstrated that depletion of RAD51B by CRISPR/Cas9 enhanced the recruitment of PRC2 to Esr1 promoter and resulted in the modification of H3K27me3 in this region, leading to the repression of ERα protein and the switch from ERα-positive breast cancer to an ERα-negative type.